Levetiracetam in Treating Patients With Seizures Caused by Brain Metastases

• Status: Withdrawn
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Anticonvulsant drugs, such as levetiracetam, may help control seizures caused by brain metastases.

PURPOSE: This clinical trial is studying the side effects and how well levetiracetam works in treating patients with seizures caused by brain metastases.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Northwestern University
• Collaborator: National Cancer Institute (NCI)
• Treatments: Etiracetam; Levetiracetam; Piracetam

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed solid tumor

• Pathological confirmation of brain metastasis is not required provided the clinical and neuroradiographic picture is typical

• Has had at least one prior seizure due to brain metastasis

PATIENT CHARACTERISTICS:

• Life expectancy ≥ 12 weeks

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• Absolute neutrophil count ≥ 1,500/mm³

• Platelet count ≥ 100,000/mm³

• Hemoglobin ≥ 10 g/dL

• BUN < 5 times upper limit of normal (ULN)

• Creatinine < 5 times ULN

• Bilirubin < 1.5 times ULN

• AST and ALT ≤ 3 times ULN

• Alkaline phosphatase ≤ 2 times ULN

• No allergy to levetiracetam

PRIOR CONCURRENT THERAPY:

• Prior levetiracetam allowed provided it was initiated within the past 14 days

• Other concurrent anticonvulsant monotherapy allowed provided therapy was initiated within the past 30 days